Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial 14.4 Chronic Kidney Disease The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dosage of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
This is also where some people notice changes beyond the scale
Even after a 20-week washout period, the semaglutide-intensified treatment group maintained lower testosterone and LH levels, LH/FSH ratio, fasting insulin, and HOMA-IR, suggesting that semaglutide injections could improve insulin resistance and modulate androgen and sex hormone levels in patients living with obesity and infertility
Source: Californiaherps Cute huh
Independent testing results for quality and purity
